- JAMA Oncology
- 1 comment
Durvalumab demonstrates favourable clinical activity against locally advanced/ metastatic urothelial cancer
Phase 1/2 open-label study reveals durvalumab could be an attractive alternative to chemotherapy in urothelial cancer
Recommended in Oncology
- The Lancet Oncology
- FULLTEXT
Preventive treatments for cancer: a review
- Clinical Essentials from FDA
- FULLTEXT
FDA approves olaparib maintenance therapy for ovarian cancer
- JCO Oncology Journals
- FULLTEXT
Is metastasis-free survival a valid surrogate for overall survival in patients with localized prostate cancer?
New in Oncology
- Clinical Essentials from J Natl Compr Canc Netw
- 1 comment
Breast cancer: extended tamoxifen tops ovarian ablation/AI therapy
Lifetime outcomes are better, and costs lower, with continued tamoxifen.
- Clinical Essentials from BJU Int
- 1 comment
mpMRI tops biopsy for identifying aggressive apical prostate cancer
MRI can be useful for planning the extent of apical preservation during prostatectomy
- Clinical Essentials from Eur J Cancer
- 1 comment
Rare hematologic malignancies: survival outcomes in the 21st century
Unmet treatment needs persist for many malignancies.
- Clinical Essentials from Ann Surg Oncol
- 1 comment
HPV+ OPSCC: adjuvant therapy reduces recurrence risk
Adjuvant therapy improves outcomes after transoral resection.
- Clinical Essentials from J Clin Oncol
- no comment
MCRPC: low-dose cabazitaxel is safer alternative in second-line setting
PROSELICA trial compared 20 and 25 mg/m2 dosing regimens
- Univadis Medical News
- 1 comment
Consuming energy-dense food may increase obesity-related cancer risk in people of normal weight
Experts suggest that higher dietary energy density in normal-weight women may lead to metabolic dysregulation independent of body weight.
- Univadis Medical News
- no comment
Patient participation in hand hygiene initiatives should not be seen as a threat
Almost half of physicians feel patients should not be offering reminders to perform hand hygiene.
- Univadis Medical News
- 1 comment
UK has witnessed a marked decline in colorectal cancer deaths
Trend attributed to screening programmes and better treatments.
- Univadis Medical News
- 1 comment
DPP-4 inhibitors not linked to cancer risk, says meta-analysis
No apparent risk for with of the individual drugs in the class.
- Clinical Essentials from J Clin Oncol
- 1 comment
- FULLTEXT
Stage IV NSCLC: new ASCO guidelines for systemic therapy
Recommendations include data from 20 new clinical trials.
- Clinical Essentials from FDA
- 1 comment
- FULLTEXT
Besponsa wins FDA approval for relapsed/refractory ALL
Phase 3 INO-VATE data show superior CR rate and duration vs standard chemotherapy.
- Clinical Essentials from J Clin Pharmacol
- 1 comment
- FULLTEXT
Ixazomib DDI study recommends against concomitant CPY3A inducers
No clinically meaningful effect with CYP3A inhibitors.
- Clinical Essentials from J Am Acad Dermatol
- 1 comment
Multiple primary melanoma: outcomes linked to genetic factors
Understanding risk factors can help guide treatment of MPM.
- Clinical Essentials from Cancer Epidemiol Biomarkers Prev
- 1 comment
Breast cancer: diuretics, β-blockers tied to poorer outcomes
Results of the SEER-Medicare analysis suggest switching to ARBs, CCBs, or ACE inhibitors.
Professional & Business
- International Medical Press
Third of trainee GPs plan to leave NHS within 6 months
- International Medical Press
Proposed cuts to sexual health services deemed ‘unsafe’
- International Medical Press
